×

Advanced Drug Delivery CDMO Market Size, Share and Analysis Research Report 2027

The Global Advanced Drug Delivery CDMO Market is expected to witness a healthy and a double-digit growth rate by 2027. Major advantages offered by advanced drug delivery systems such as targeted and controlled release of new molecules to sites, ease of use, no requirement for frequent dosing, growing demand for safer, more effective methods of administering drugs to patients, evolving landscape of drug molecules, favorable investment by private equity companies and investors are some of the key factors driving the demand for advanced drug delivery systems (ADDSs) and advanced drug delivery CDMOs.

Advanced drug delivery systems are increasingly being used for targeted and controlled release of novel molecules in tissues and cells to optimize their potential benefits for patients.

Major Advantages Offered by Advanced Drug Delivery Systems Fuels the Advanced Drug Delivery CDMO Market Growth

Advanced drug delivery systems have emerged as an easy and accurate method of delivering the drug to a specific site. These systems offer many advantages over traditional systems such as targeted and controlled release of new molecules to sites, consistent absorption of the drug, no requirement of frequent dosing, reduced variability in systemic drug concentrations, and reduction in toxic metabolites. Advanced drug delivery systems optimize drug performance and help deliver superior outcomes, which in turn lead has led to increased demand for advanced drug delivery CDMOs.

 “Advanced drug delivery CDMOs will play a pivotal role in advancing the science of drug delivery. The advanced drug delivery technologies will make medicines that are easier to use, and require less frequent dosing, which in turn will enable patients to spend less time managing their diseases.”-Senior Scientist, Advanced Drug Delivery CDMO, U.S.A

Private Equity Companies & Investors Investment in Advanced Drug Delivery CDMOs Drives the Global Advanced Drug Delivery CDMO Market

Citing the lucrative growth prospects of the global advanced drug delivery systems market, many private equity companies & investors have invested in the advanced drug delivery CDMO market.

For instance,

  • In December 2022, EQT Future and ATHOS, alongside other co-investors, invested in SHL Medical, a leading provider of advanced drug delivery solutions
  • In September 2021, ADQ, an Abu Dhabi-based holding company acquired Acino, a leader in advanced drug delivery systems. Through the investment, ADQ intends to develop an integrated pharma platform including advanced drug development, in-licensing, manufacturing, and commercialization capabilities in select growth-leading markets

Advanced Drug Delivery CDMO Market

Competitive Landscape Analysis: Advanced Drug Delivery CDMO Market

Some of the key players operating in the advanced drug delivery CDMO market are Evonik Health Care, SHL Medical, Lubrizol Life Science, Acino International AG, Pharmathen, Phillips-Medisize (A Molex Company), etc.

Organic and Inorganic Growth Strategies Adopted by the Market Players to Establish Their Foothold in the Advanced Drug Delivery CDMO Market

Players operating in the global advanced drug delivery CDMO market are adopting aggressive growth strategies such as acquiring related firms, launching new products and entering into mergers & collaborations to garner a higher market share.

For instance,

  • In July 2023, SHL Medical, a leading provider of advanced drug delivery solutions acquired LCA Automation, a Swiss innovative automation solutions provider. The acquisition of LCA Automation is aligned with SHL Medical’s strategy to cater to the growing market demand for drug delivery solutions, expand its global presence, and strengthen its vertical capabilities globally
  • In July 2021, Partners Group, a leading global private markets firm agreed to acquire Pharmathen from from BC Partners. Pharmathen is a leading CDMO specializing in advanced drug delivery technologies for complex generic pharmaceutical products.

The global advanced drug delivery CDMO market is expected to gain a consistent momentum in the forthcoming years due to favorable investments by private equity companies and investors, an increased adoption of controlled-release drug delivery systems by patient populations, and aggressive organic and inorganic growth strategies followed by the global market players.

 

Key Strategic Questions Addressed in this Research Report are as follows:-

  • What is the market size and forecast for the advanced drug delivery CDMO market?
  • What are the historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the advanced drug delivery CDMO market?
  • What are the major growth drivers, restraints/challenges impacting the global advanced drug delivery CDMO market?
  • What are the opportunities prevailing in the advanced drug delivery CDMO market?
  • What is the investment landscape of the advanced drug delivery CDMO market?
  • Which region has the highest share in the market? Which region is expected to witness the highest growth rate in the next 5 years?
  • Who are the major players operating in the market? What is the competitive positioning of key players?
  • Who are the new players entering the global advanced drug delivery CDMO market?
  • What are the key strategies adopted by players working in advanced drug delivery CDMO market?

1. Research Methodology
1.1. Secondary Research
1.2. Primary Research
1.3. Market Estimation
1.4. Market Forecasting

2. Executive Summary

3. Market Overview
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunities
3.2. Industry Speaks

4. Advanced Drug Delivery CDMO Market - Size & Forecast (2019-2027), By Services
4.1. Development and Manufacturing Services
4.2. Analytical Services
4.3. Assembly, Labelling and Packaging
4.4. Other Services

5. Advanced Drug Delivery CDMO Market - Size & Forecast (2019-2027), By Region
5.1. North America (U.S. & Canada)
5.2. Europe (UK, Germany, France, Italy, Spain, Rest of Europe)
5.3. Asia Pacific (China, India, Japan, Rest of Asia Pacific)
5.4. Rest of the World (Latin America, Middle East & Africa)

6. Competitive Landscape
6.1. Key Players and their Competitive Positioning
6.1.1. Competitive Positioning of Key Players (2022)
6.1.2. Service Offerings Assessment, By Players
6.2. Key Strategies Assessment, By Player (2021-2023)
6.2.1. New Service Launches
6.2.2. Partnerships, Agreements, & Collaborations
6.2.3. Mergers & Acquisitions
6.2.4. Other Developments

7. Key Companies Scanned (Indicative List)
7.1. Evonik Health Care
7.2. SHL Medical
7.3. Phillips-Medisize - A Molex Company
7.4. Lubrizol Life Science
7.5. Acino International AG
7.6. Pharmathen
7.7. Other Players

The study has been compiled based on the extensive primary and secondary research.

Secondary Research (Indicative List)

Advanced Drug Delivery CDMO Market

Primary Research

To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand side stakeholders.

Supply Side Stakeholders:

  • Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
  • Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants

Demand Side Stakeholders:

  • Stakeholders in Hospitals, Clinics and Other End Users.

Breakdown of Primary Interviews

Advanced Drug Delivery CDMO Market

Market Size Estimation

Both ‘Top-Down and Bottom-Up Approaches’ were used to derive market size estimates and forecasts.

Data Triangulation

Research findings derived through secondary sources & internal analysis were validated with Primary Interviews, Internal Knowledge Repository, and Company Sales Data.

Advanced Drug Delivery CDMO Market

Advanced Drug Delivery CDMO Market